Agios Pharmaceuticals announced layoffs of 100 employees on November 5, 2026. Agios cut over 100 research and development roles, more than 35 percent of its R&D group. The FDA pushed its sickle cell decision on mitapivat to February 1, and spend is shifting to commercial work.